Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Four RNAi-Related Patent Applications: Mar 2, 2006


Title: Methods for Treating Cancer Using Anti-Wnt2 Monoclonal Antibodies and siRNA

Number: 20060040883

Filed: May 16, 2005

Lead Inventor: Liang You, University of California

The invention "relates to methods of inhibiting the growth of cells, in particular cancer cells, that overexpress Wnt2," the patent application's abstract states. "The methods comprise contacting the cell with an agent that binds to Wnt2 mRNA or Wnt2 protein, interferes with Wnt2 signaling or inhibits binding of the Wnt2 protein to another protein, such as a Frizzled receptor."

Title: Compositions and Methods for Enhancing Delivery of Nucleic Acids into Cells and for Modifying Expression of Target Genes in Cells

Number: 20060040882

Filed: May 4, 2005

Lead Inventor: Lishan Chen, Nastech Pharmaceutical

"Polynucleotide delivery-enhancing polypeptides are admixed or complexed with, or conjugated to, nucleic acids for enhancing delivery the nucleic acids into cells," the patent application's abstract states. "The transported nucleic acids are active in target cells as small inhibitory nucleic acids that modulate expression of target genes, mediated at least in part by RNA interference. The siNA/polypeptide compositions and methods of the invention provide effective tools to modulate gene expression and alter phenotype in mammalian cells, including by altering phenotype in a manner that eliminates disease symptoms or alters disease potential in targeted cells or subject individuals to which the siNA/polypeptide compositions are administered."

Title: RNA Interference Vectors

Number: 20060040391

Filed: Aug. 20, 2004

Lead Inventor: Cheryl Bailey, Promega

According to the patent application's abstract, the invention "relates to gene-specific silencing through RNA interference, and in particular, to vectors for expressing RNAi molecules. In some embodiments, the present invention provides compositions and methods for inducible expression of RNAi molecules, and/or for long-term expression of RNAi molecules. Hence the compositions and methods described herein are suitable for regulatable and/or sustained gene-specific silencing in cells," the abstract states.

Title: Methods, Compositions, and Kits Comprising RNA for RNA Interference

Number: 20060040290

Filed: June 23, 2005

Inventor: Gerald Zon, Applera

The invention, the patent application's abstract states, relates "to methods, compositions, and kits for reducing the amount of a target polynucleotide sequence. In some embodiments, block oligomers comprising peptide nucleic acids are hybridized to an anti-sense strand to form an anti-sense complex comprising regions with desirable thermodynamic characteristics. In some embodiments, the expression of a target messenger RNA is reduced in RNA interference experiments using anti-sense compositions comprising PNAs."

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.